Marksans Pharma share news and announcements
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Formerly Tasc Pharmaceuticals
Last close ₹286.90down ₹7.55 (2.56%)BSE ₹286.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹294.45.
52-week range of traded prices to 23 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹13,001 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 4.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 12 Aug 2026
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 14,14,61953.0% delivered
Marksans Pharma share news and announcements
682 announcements, routine notices left out, newest first. Page 2 of 14.
Nov 2025
Oct 2025
27 Oct · General Updates
8 Oct · Rating
Sep 2025
24 Sep · Options to purchase securities
22 Sep · Analysts
16 Sep · Updates
Aug 2025
12 Aug · Board meeting
5 Aug · Analysts
Jul 2025
25 Jul · Board meeting
25 Jul · Board meeting
11 Jul · Board meeting
Jun 2025
May 2025
9 May · Analysts
Apr 2025
Mar 2025
21 Mar · Analysts
5 Mar · Rating
Feb 2025
11 Feb · Results